APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION

The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system. Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vasc...

詳細記述

書誌詳細
主要な著者: T. V. Martynyuk, Z. H. Dadacheva, V. M. Paramonov, O. A. Arkhipova, S. N. Nakonechnikov, I. Ye. Chazova
フォーマット: 論文
言語:Russian
出版事項: InterMedservice 2015-06-01
シリーズ:Евразийский Кардиологический Журнал
主題:
オンライン・アクセス:https://www.heartj.asia/jour/article/view/5633